KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.98

Characteristics and outcome of synchronous bilateral Wilms tumour in the SIOP WT 2001 Study: Report from the SIOP Renal Tumour Study Group (SIOP-RTSG).

Hélène Sudour-Bonnange, Harm van Tinteren, Gema L Ramírez-Villar, Jan Godzinski, Sabine Irtan, Manfred Gessler, Tanzina Chowdhury, Georges Audry, Joerg Fuchs, Mark Powis, Cornelis P van de Ven, Bruce Okoye, Naima Smeulders, Gordan M Vujanic, Arnaud Verschuur, Aurore L'Herminé-Coulomb, Beatriz de Camargo, Joaquim Caetano de Aguirre Neto, Jens Peter Schenk, Mary M van den Heuvel-Eibrink, Katy Pritchard-Jones, Norbert Graf, Christophe Bergeron, Rhoikos Furtwängler

Br J Cancer 131(6) 972-981

PMID39080350
PMCIDPMC11405756
DOI10.1038/s41416-024-02799-0
发表日期2024-07-30
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
摘要

摘要

BACKGROUND: Among patients with nephroblastoma, those with bilateral disease are a unique population where maximising tumour control must be balanced with preserving renal parenchyma. METHODS: The SIOP 2001 protocol recommended surgery after neoadjuvant cycle(s) of Dactinomycin and Vincristine (AV) with response-adapted intensification, if needed. Adjuvant treatment was given based on the lesion with the worst histology. RESULTS: Three hundred and twenty seven patients with stage V disease were evaluable: 174 had bilateral Wilms tumour (BWT), 101 unilateral WT and contralateral nephroblastomatosis (NB) and 52 bilateral nephroblastomatosis. In these three groups, the estimated 5y-EFS was 76.1%, 84.6%, and 74.9%, respectively. AV chemotherapy alone was the successful chemotherapy for 58.7% of all the patients and 65.6% of the non-metastatic patients. Among the 174 patients with BWT, 149 (88.2%) had at least one nephron-sparing surgery. Twenty of 61 bilateral stage I patients were treated with four-week AV postoperatively achieving 94.4% 5y-EFS. At last follow-up, 87% of patients had normal renal function. CONCLUSIONS: This study demonstrates that AV without anthracyclines is sufficient to achieve NSS and good survival in the majority of patients. For patients with bilateral stage I WT and intermediate risk histology, only four weeks adjuvant AV seems to be sufficient. CLINICAL TRIAL REGISTRATION: NCT00047138.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。